Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. [electronic resource]
Producer: 20100309Description: 1053-62 p. digitalISSN:- 1538-7445
- Angiogenesis Inhibitors -- pharmacology
- Animals
- Blotting, Western
- Carcinoma, Renal Cell -- blood supply
- Cell Line
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Endothelial Cells -- cytology
- Endothelium, Vascular -- drug effects
- Female
- Humans
- Indoles -- pharmacology
- Kidney Neoplasms -- blood supply
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Neovascularization, Pathologic -- genetics
- Pyrroles -- pharmacology
- RNA Interference
- Receptor, Platelet-Derived Growth Factor beta -- genetics
- Sunitinib
- Tumor Burden -- drug effects
- Vascular Endothelial Growth Factor Receptor-2 -- genetics
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.